Abbott (ABT) Gets CE Mark for World's First Dual Glucose-Ketone Sensor

Abbott Laboratories (NYSE:ABT) announced on May 27 that it has secured CE Mark for the world's first dual glucose-ketone sensing technology for people with diabetes. The systems are branded as Libre Duo and Libre Duo 10 Day.

The Product

Libre Duo is the first system to combine continuous glucose monitoring (CGM) and ketone measurement in a single device, allowing real-time tracking of both glucose and ketone levels. This helps prevent diabetic ketoacidosis (DKA), especially in type 1 diabetes patients.

Pricing and Availability

Abbott has not yet disclosed pricing or a commercial launch date in European markets. It is expected to be available in CE Mark-recognizing countries in the coming months.

Competition

Abbott faces competition from companies like Dexcom in the CGM market, but the dual ketone technology gives it a unique competitive edge. Existing Libre devices already hold significant market share.

Potential Impact on the Company

Libre Duo is expected to strengthen Abbott's position in the diabetes management market and drive revenue growth in the healthcare segment. The innovation also reinforces Abbott's reputation as a leader in medical technology.